Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009348 | 0.92 | GRM5 (0.54) | GRM5TSHRPTGS1PTGS2CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL2015764 | 0.88 | GRM5 (0.56) | GRM5TSHRPTGS1PTGS2CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL30795336 | 0.84 | GRM5 (0.46) | GRM5TSHRCYP1A2KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2014232 | 0.84 | GRM5 (0.46) | GRM5TSHRCYP1A2KCNH2 | |
| SCHEMBL2013482 | 0.82 | GRM5 (0.60) | GRM5TSHRCYP1A2 | |
| SCHEMBL2010249 | 0.80 | GRM5 (0.49) | GRM5TSHRCYP1A2 | |
| SCHEMBL2010940 | 0.79 | GRM5 (0.62) | GRM5TSHRPTGS1PTGS2CYP1A2 | |
| SCHEMBL2012435 | 0.75 | GRM5 (0.47) | GRM5TSHRCYP1A2 | |
| SCHEMBL2014419 | 0.74 | GRM5 (0.53) | GRM5TSHRCYP1A2 | |
| SCHEMBL30796732 | 0.74 | GRM5 (0.53) | GRM5TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040707-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | claimed |
| EP-2513117-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-28 | — | — | EP | claimed |
| EP-2513117-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | claimed |
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-11 | — | — | US | claimed |
| WO-2011073339-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-9040707-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| EP-2513117-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-28 | — | — | EP | disclosed |
| EP-2513117-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-11 | — | — | US | disclosed |
| WO-2011073339-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM2 | GRM5 1/4885TSHR 303/4885PTGS1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.